Cerebrotendinous xanthomatosis-associated diarrhea and response to chenodeoxycholic acid treatment.
Cerebrotendinous xanthomatosis (CTX)
Chenodeoxycholic acid (CDCA)
diarrhea
Journal
JIMD reports
ISSN: 2192-8304
Titre abrégé: JIMD Rep
Pays: United States
ID NLM: 101568557
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
31
05
2020
revised:
08
08
2020
accepted:
12
08
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
In patients with cerebrotendinous xanthomatosis (CTX), chronic diarrhea is one of the earliest and main symptoms of the disease. In the current study, we evaluated the characteristics of the diarrhea and its response to chenodeoxycholic acid (CDCA) therapy in a cohort of Dutch CTX patients. We performed a retrospective review of medical records for 33 genetically confirmed CTX patients, and abstracted the characteristics of the diarrhea and the response to CDCA therapy (15 mg/kg/day up to 750 mg/day). The Bristol Stool Scale (BSS) was used for qualitative characterization of the stool. Twenty-five patients had diarrhea documented at baseline (76%). Of these patients, 10 had diarrhea rated as 6 (fluffy pieces with ragged edges, a mushy stool), and 6 had diarrhea rated as 7 (watery, no solid pieces, entirely liquid) using the BSS. In 10 patients for whom data were recorded, the median stool frequency at baseline was 3 per day (range 2-6 per day). The response rate with CDCA for diarrhea resolution was 100% based on at least one post-baseline visit without diarrhea and 95% as assessed at the first post-baseline visit. In 68% of cases resolution was complete and sustained as no episodes of diarrhea were documented for follow-up periods as long as 25 years. Chronic diarrhea persisting for years without spontaneous remission is a common feature of CTX at diagnosis. Chenodeoxycholic acid is an effective treatment for symptomatic relief of diarrhea in patients with CTX.
Sections du résumé
BACKGROUND
BACKGROUND
In patients with cerebrotendinous xanthomatosis (CTX), chronic diarrhea is one of the earliest and main symptoms of the disease. In the current study, we evaluated the characteristics of the diarrhea and its response to chenodeoxycholic acid (CDCA) therapy in a cohort of Dutch CTX patients.
METHODS
METHODS
We performed a retrospective review of medical records for 33 genetically confirmed CTX patients, and abstracted the characteristics of the diarrhea and the response to CDCA therapy (15 mg/kg/day up to 750 mg/day). The Bristol Stool Scale (BSS) was used for qualitative characterization of the stool.
RESULTS
RESULTS
Twenty-five patients had diarrhea documented at baseline (76%). Of these patients, 10 had diarrhea rated as 6 (fluffy pieces with ragged edges, a mushy stool), and 6 had diarrhea rated as 7 (watery, no solid pieces, entirely liquid) using the BSS. In 10 patients for whom data were recorded, the median stool frequency at baseline was 3 per day (range 2-6 per day). The response rate with CDCA for diarrhea resolution was 100% based on at least one post-baseline visit without diarrhea and 95% as assessed at the first post-baseline visit. In 68% of cases resolution was complete and sustained as no episodes of diarrhea were documented for follow-up periods as long as 25 years.
CONCLUSIONS
CONCLUSIONS
Chronic diarrhea persisting for years without spontaneous remission is a common feature of CTX at diagnosis. Chenodeoxycholic acid is an effective treatment for symptomatic relief of diarrhea in patients with CTX.
Identifiants
pubmed: 33204601
doi: 10.1002/jmd2.12163
pii: JMD212163
pmc: PMC7653248
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105-111Informations de copyright
© 2020 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.
Déclaration de conflit d'intérêts
Aad Verrips received honoraria from serving as a consultant for Leadiant Biosciences. Bianca M.L. Stelten reports no conflict of interest. Eric P. Brass is a consultant for Leadiant Biosciences.
Références
J Inherit Metab Dis. 1992;15(3):374-6
pubmed: 1405473
J Inherit Metab Dis. 2018 Jul;41(4):647-656
pubmed: 29484516
Am J Ophthalmol. 1991 Nov 15;112(5):606-7
pubmed: 1951610
Eur J Pediatr. 2016 Jan;175(1):143-6
pubmed: 26156051
JIMD Rep. 2020 Aug 30;56(1):105-111
pubmed: 33204601
Neurol Sci. 2020 Apr;41(4):943-949
pubmed: 31863326
BMJ. 1990 Feb 17;300(6722):439-40
pubmed: 2107897
Pediatrics. 2009 Jan;123(1):143-7
pubmed: 19117873
J Biol Chem. 1991 Apr 25;266(12):7779-83
pubmed: 2019602
Clin Neuropharmacol. 2013 May-Jun;36(3):78-83
pubmed: 23673909
Arch Neurol. 2000 Apr;57(4):520-4
pubmed: 10768627
J Inherit Metab Dis. 1988;11(1):56-75
pubmed: 3128689
Neurology. 2019 Jan 8;92(2):e83-e95
pubmed: 30530799
Acta Paediatr. 1996 Aug;85(8):932-6
pubmed: 8863874
J Clin Lipidol. 2018 Sep - Oct;12(5):1169-1178
pubmed: 30017468
Acta Paediatr. 2001 Jul;90(7):828-9
pubmed: 11519995